Samantha Paulina Peña-Lozano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samantha Paulina Peña-Lozano has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Julia Esther Colunga Pedraza
Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico and Francisco I. Madero Pte., s/n, and Gonzalitos Avenue, Colonia Mitras Centro, Monterrey, NL, Mexico
4 shared publications - Andrés Gómez-De León
Hematology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autonoma de Nuevo León, Monterrey, Mexico
3 shared publications - Perla Rocío Colunga Pedraza
Servicio de Hematología, Hospital Universitario Dr José Eleuterio González, UANL, Monterrey, Mexico
3 shared publications - David Gómez-Almaguer
Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México
2 shared publications - Olga Graciela Cantú-Rodríguez
Hematology Department, Internal Medicine Division, Dr. José Eleuterio González University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico
2 shared publications - Oscar González-Llano
Universidad Autonóma de Nuevo León
2 shared publications
Latest Publications
- Open Access
- 18 August 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S193-S201
Overcoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center
- 18 August 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S193-S201
Open AccessOvercoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center
- Open Access
- 30 August 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 971-976
Diagnosis and treatment of acute lymphoblastic leukemia in Latin America
To discuss the status and challenges associated with the management of acute lymphoblastic leukemia (ALL) in Latin America.This review summarizes various insights gained from information regarding ...
- 30 August 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 971-976
Open AccessDiagnosis and treatment of acute lymphoblastic leukemia in Latin America
To discuss the status and challenges associated with the management of acute lymphoblastic leukemia (ALL) in Latin America.This review summarizes various insights gained from information regarding ...
- 26 April 2022
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 54 (2) , 360-366
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature
Immune thrombocytopenia (ITP) is an autoimmune disease that results from antibody-mediated platelet destruction and impaired platelet production. Novel therapies have emerged in the last decade, but 15–20% of patients will relapse or fail and require further therapy. We performed a prospective, single-arm intervention study on seven patients with chronic, persistent, or refractory ITP from the Hospital Universitario “Dr. José E González”, in Monterrey, Mexico between 2015 and 2019. Eligible patients received oral oseltamivir 75 mg twice daily for 5 days and were followed up for six months. Most patients received a median of three distinct therapies (range 2–6). Four patients (57.1%) received combined therapy. The median time for any response was 55.5 days (range = 14–150). All patients responded at some point in time (ORR = 100%, six had a proportion of loss of response [PR], and one achieved [CR]). Six months after oseltamivir administration, three patients (42.9%) maintained a response, and one patient had a CR (14.3%). Oseltamivir was well tolerated with a good overall response rate and was useful for treating chronic ITP. We observed an initial increase in the number of platelets; however, this response was not maintained.
- 26 April 2022
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 54 (2) , 360-366
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature
Immune thrombocytopenia (ITP) is an autoimmune disease that results from antibody-mediated platelet destruction and impaired platelet production. Novel therapies have emerged in the last decade, but 15–20% of patients will relapse or fail and require further therapy. We performed a prospective, single-arm intervention study on seven patients with chronic, persistent, or refractory ITP from the Hospital Universitario “Dr. José E González”, in Monterrey, Mexico between 2015 and 2019. Eligible patients received oral oseltamivir 75 mg twice daily for 5 days and were followed up for six months. Most patients received a median of three distinct therapies (range 2–6). Four patients (57.1%) received combined therapy. The median time for any response was 55.5 days (range = 14–150). All patients responded at some point in time (ORR = 100%, six had a proportion of loss of response [PR], and one achieved [CR]). Six months after oseltamivir administration, three patients (42.9%) maintained a response, and one patient had a CR (14.3%). Oseltamivir was well tolerated with a good overall response rate and was useful for treating chronic ITP. We observed an initial increase in the number of platelets; however, this response was not maintained.
- Open Access
- 10 December 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (7) , e29498
Cancer does not wait: Safeguarding care for pediatric acute lymphoblastic leukemia patients during the COVID‐19 pandemic in a Mexican hospital
- 10 December 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (7) , e29498
Open AccessCancer does not wait: Safeguarding care for pediatric acute lymphoblastic leukemia patients during the COVID‐19 pandemic in a Mexican hospital
- 27 May 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (9) , 2287-2290
Outpatient transplantation in the COVID-19 era: a single-center Latin American experience
- 27 May 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (9) , 2287-2290
Outpatient transplantation in the COVID-19 era: a single-center Latin American experience